{"id":89257,"date":"2026-05-12T22:26:50","date_gmt":"2026-05-13T04:26:50","guid":{"rendered":"https:\/\/trimrx.com\/blog\/?p=89257"},"modified":"2026-05-13T16:46:12","modified_gmt":"2026-05-13T22:46:12","slug":"cjc-1295-dosing-protocol","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/cjc-1295-dosing-protocol\/","title":{"rendered":"CJC-1295 Dosing Protocol: Cycling, Frequency & Best Practices"},"content":{"rendered":"

Introduction<\/h2>\n

CJC-1295 dosing varies dramatically between published clinical trials and the protocols sold by compounding pharmacies and anti-aging clinics. The Teichman 2006 Phase 1 trial used 30 to 250 mcg\/kg per dose, which translates to 2.4 to 20 mg for an 80 kg adult. Real-world prescribed protocols typically use 1 to 2 mg per week of the DAC version, or 100 to 300 mcg of the no-DAC version once or twice daily.<\/p>\n

This guide covers what doses were actually studied, what’s commonly prescribed today, how cycling protocols are structured, and where you should monitor lab values during a cycle. None of the real-world protocols come from controlled dose-finding trials, so they reflect prescriber convention rather than rigorous evidence.<\/p>\n

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n

What Doses Did the Original Trials Use?<\/h2>\n

The Teichman et al. 2006 Phase 1 trial in The Journal of Clinical Endocrinology and Metabolism tested single subcutaneous doses of 30, 60, 125, and 250 mcg\/kg in 21 healthy adults. The 60 mcg\/kg dose was identified as effective with manageable side effects. At 125 mcg\/kg and above, IGF-1 commonly exceeded the upper limit of normal.<\/p>\n

Quick Answer: Clinical trials used 30 to 250 mcg\/kg, far higher than current clinic doses of 1 to 2 mg per week<\/p>\n

For an 80 kg adult, 60 mcg\/kg is 4.8 mg. That’s roughly 2 to 5 times higher than what most compounding pharmacies dispense per dose today. The reduction in real-world dosing reflects safety concerns about chronic supraphysiologic IGF-1 elevation rather than published evidence that lower doses work as well.<\/p>\n

The discontinued Phase 2 trial in HIV lipodystrophy used 1 to 2 mg once weekly for 12 weeks. This is closer to current clinical practice and likely the origin of the 1 to 2 mg weekly convention.<\/p>\n

What’s the Standard Dose for CJC-1295 with DAC?<\/h2>\n

Most compounding pharmacies dispense CJC-1295 with DAC at 1 to 2 mg per weekly injection.<\/strong> Some clinics start at 1 mg weekly and titrate up based on IGF-1 response. The dose is given subcutaneously, usually in the abdomen, anterior thigh, or upper arm.<\/p>\n

Once-weekly dosing matches the roughly 8-day half-life. Twice-weekly dosing has been used in some protocols, with 0.5 to 1 mg per dose, but there’s no published evidence this is superior. The pulsatile GH response continues for 6 days after a single dose in the Phase 1 data, so once-weekly should be sufficient to maintain elevated IGF-1.<\/p>\n

Higher doses don’t proportionally increase benefit but do increase side effect rates and IGF-1 levels. Doses above 2 mg per week are uncommon in current practice.<\/p>\n

How Is CJC-1295 Without DAC Dosed?<\/h2>\n

The no-DAC version (sometimes labeled “mod GRF 1-29” or “CJC-1295 no DAC”) is typically dosed 100 to 300 mcg subcutaneously, once or twice daily.<\/strong> The shorter half-life of about 30 minutes means daily injections are needed to maintain regular pituitary stimulation.<\/p>\n

A common protocol is 100 to 300 mcg at bedtime, with the goal of amplifying the natural GH pulse that occurs during early slow-wave sleep. Some users add a second dose in the morning or post-workout for two daily injections. Most protocols cap at three doses per day.<\/p>\n

The no-DAC version is often paired with ipamorelin at the same dose. The combination is injected from a single vial when compounded together, which is the most common form sold by anti-aging clinics.<\/p>\n

What Does a Typical Cycle Look Like?<\/h2>\n

Standard cycles run 8 to 12 weeks of active dosing followed by a 4-week washout.<\/strong> The rationale is to limit sustained IGF-1 elevation and let the pituitary feedback loop reset. Some protocols use 5-days-on, 2-days-off weekly micro-cycling, particularly with the no-DAC version.<\/p>\n

There’s no published trial data supporting any particular cycle structure. The conventions come from anabolic steroid culture and bodybuilding community practice rather than endocrinology research. Whether cycling actually reduces long-term risk is unknown.<\/p>\n

Continuous dosing without cycling has been used in some HIV lipodystrophy and adult GH deficiency settings. For healthy adults using CJC-1295 off-label for body composition or longevity goals, the cycle structure is essentially arbitrary.<\/p>\n

How Should You Time Injections?<\/h2>\n

For the no-DAC version, bedtime dosing matches the natural GH pulse during slow-wave sleep, which begins about 30 to 60 minutes after sleep onset.<\/strong> Injecting 30 minutes before bed lets the peptide be active during the body’s largest natural GH release of the day. Bowers et al. 1990 in JCEM showed that GHRH and ghrelin agonists amplify the existing nocturnal pulse more effectively than they create new ones.<\/p>\n

Pre-workout dosing is favored by some protocols for its potential effect on workout recovery, but published evidence is absent. Post-workout dosing competes with the body’s natural post-exercise GH release.<\/p>\n

For the DAC version, timing matters less because the drug is active continuously. Weekly injections can be given any day, but consistency on the same day each week is the standard recommendation for compliance.<\/p>\n

Key Takeaway: No-DAC version is typically dosed 100 to 300 mcg once or twice daily, often at bedtime<\/p>\n

What Injection Site and Technique Should You Use?<\/h2>\n

CJC-1295 is administered subcutaneously, not intramuscularly.<\/strong> The most common sites are the abdomen at least two inches from the navel, the anterior or lateral thigh, and the back of the upper arm. Insulin syringes with 29 to 31 gauge needles, 5\/16 to 1\/2 inch length, are standard.<\/p>\n

Rotating injection sites reduces local skin reactions, which were reported in 80 percent of subjects in the Teichman trial. The site reactions typically present as transient redness, mild swelling, or itching at the injection point and resolve within 24 to 48 hours.<\/p>\n

Reconstituted peptide should be refrigerated and used within 30 days. Bacteriostatic water is the standard reconstitution diluent because it preserves the peptide stability with benzyl alcohol as a preservative.<\/p>\n

What Labs Should You Monitor During a Cycle?<\/h2>\n

IGF-1 every 4 to 6 weeks is the core safety check.<\/strong> The therapeutic target is restoring IGF-1 to the middle of the age-adjusted normal reference range. Levels above the upper limit indicate the dose is too high. Levels at or below baseline indicate the dose is too low or the pituitary isn’t responding.<\/p>\n

Fasting glucose and HbA1c at baseline and every 12 weeks track for impaired glucose tolerance, a known risk of chronic GH\/IGF-1 elevation. The Liu et al. 2007 Annals of Internal Medicine meta-analysis of GH in healthy older adults found measurable increases in glucose intolerance with chronic use.<\/p>\n

Age-appropriate cancer screening is the third leg. Prostate-specific antigen for men over 50, mammography for women per standard guidelines, and colonoscopy timing per standard schedule. Sustained IGF-1 elevation is associated with increased prostate, breast, and colorectal cancer risk in epidemiological data.<\/p>\n

How Does CJC-1295 Compare to GLP-1 Medication Dosing?<\/h2>\n

GLP-1 medications like semaglutide and tirzepatide use titration schedules dictated by published trial protocols and FDA labeling.<\/strong> Semaglutide starts at 0.25 mg weekly for 4 weeks, then 0.5, 1, 1.7, and 2.4 mg with monthly increases. Tirzepatide starts at 2.5 mg weekly and titrates similarly to a maximum of 15 mg. These doses come from the STEP and SURMOUNT trial programs.<\/p>\n

CJC-1295 has no equivalent regulatory dosing guidance. The conventions in current use are based on prescriber experience and the original Phase 1\/2 trial data, not on FDA-cleared labeling. For weight loss specifically, GLP-1 medication has dramatically better evidence and clearer dosing structure. TrimRx offers compounded semaglutide and tirzepatide through a personalized treatment plan based on the published trial protocols.<\/p>\n

Bottom line: IGF-1 monitoring every 4 to 6 weeks is the standard safety check<\/p>\n

FAQ<\/h2>\n

Can You Do CJC-1295 Every Day?<\/h3>\n

The DAC version no, because the long half-life would lead to drug accumulation and supraphysiologic IGF-1 over weeks of daily dosing. The no-DAC version yes, in fact daily dosing at bedtime is the standard protocol.<\/p>\n

What Happens If You Miss a Weekly Dose?<\/h3>\n

For CJC-1295 with DAC, the drug is still active in your system for several days after the missed dose. You can take it as soon as you remember within 2 to 3 days, or skip and wait for the next scheduled dose. IGF-1 won’t drop significantly from one missed weekly injection.<\/p>\n

Is the Dose Different for Men Versus Women?<\/h3>\n

Published trials didn’t show large sex-based dose differences. Most protocols use the same mg-based dosing for both. Body weight matters more than sex for response, which is why the original mcg\/kg dosing made sense even if it’s not used clinically anymore.<\/p>\n

Should You Take CJC-1295 with Food?<\/h3>\n

Food doesn’t matter directly because the drug is injected subcutaneously, not swallowed. However, large protein-rich meals shortly before or after injection can blunt the GH response because rising amino acids and glucose suppress GH release. Most protocols recommend injecting on a relatively empty stomach, especially the no-DAC version at bedtime.<\/p>\n

How Long Until I See Results?<\/h3>\n

IGF-1 rises within a week of starting weekly dosing. Subjective effects on sleep quality and recovery are commonly reported within 2 to 4 weeks. Body composition changes, if they occur, typically take 8 to 12 weeks based on the tesamorelin analog data. Most cycles are 12 weeks for that reason.<\/p>\n

Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n

<\/p>\n

Related Articles<\/h2>\n